Therapeutic implications of disorders of cell death signalling: Membranes, micro-environment, and eicosanoid and docosanoid metabolism

British Journal of Pharmacology

Volumn 166, Issue 4, 2012, Pages 1193-1210

  Davidson, J ^a   Rotondo, D ^a   Rizzo, M T ^b   Leaver, H A ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b METHODIST RESEARCH INSTITUTE   (United States)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

cell death signalling; lipids; mediators; membranes; pathophysiology; prostaglandins; therapeutics

Indexed keywords

17 PHENYL TRINOR PROSTAGLANDIN E2; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; BUTAPROST; DOCOSANOID; ENDOCANNABINOID; FATTY ACID; FLUPROSTENOL; HIGHLY UNSATURATED FATTY ACID; HYDROPEROXY FATTY ACID; ICOSANOID; ONO 8713; ONO AE 3 240; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTAGLANDIN SYNTHASE; SC 51089; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; AUTOPHAGY; BILE DUCT CANCER; BLEEDING; BONE CANCER; BRAIN INFARCTION; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL COMMUNICATION; CELL DEATH; CELL DEATH SIGNALLING; CELL MEMBRANE; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; CYTOLOGY; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DESIGN; DRUG TARGETING; ENDOMETRIUM CANCER; ENDOTHELIAL PROLIFERATION; ENDOTHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; EXCITOTOXICITY; FATTY ACID METABOLISM; GLIOBLASTOMA; GLIOMA; HEART MUSCLE CELL; HELICOBACTER PYLORI; HEMORRHAGIC SHOCK; HUMAN; LEUKEMIA; LIPIDOMICS; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; LYSOSOME MEMBRANE; MEDULLOBLASTOMA; MICROENVIRONMENT; MITOCHONDRION; MOLECULAR BIOLOGY; MOUTH CARCINOMA; MOUTH SQUAMOUS CELL CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); NEUROPROTECTION; NONHUMAN; ONCOLOGICAL PARAMETERS; OSTEOLYSIS; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REPERFUSION INJURY; RETINA ISCHEMIA; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SPINAL CORD INJURY; STELLATE CELL; STROKE; TUMOR GROWTH; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL DEATH; CELL MEMBRANE; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; ENDOCANNABINOIDS; FATTY ACIDS; HUMANS; MEMBRANE MICRODOMAINS; METABOLOMICS; MOLECULAR TARGETED THERAPY; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 84861306248     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01900.x     Document Type: Review

References (146)

1. Ackerman WE, Zhang XL, Rovin BH, Kniss DA, (2005). Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells. Biol Reprod 73: 527-535.
2. 2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40: 376-387.
3. Ahmad AS, Ahmad M, Maruyama T, Narumiya S, Dore S, (2010). Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice. Age (Dordr) 32: 271-282.
4. Ajjan RA, Grant PJ, (2008). The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf 7: 367-376.
5. Akiba S, Hatazawa R, Ono K, Hayama M, Matsui H, Sato T, (2000). Transforming growth factor-alpha stimulates prostaglandin generation through cytosolic phospholipase A(2) under the control of p11 in rat gastric epithelial cells. Br J Pharmacol 131: 1004-1010.
6. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
7. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, et al,. (2008). Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16: 487-493.
8. 2 receptor subtypes in rat retinal cultures and the neuroprotective effect of the EP2 agonist butaprost. Neurochem Int 55: 199-207.
9. Appendino G, Ligresti A, Minassi A, Cascio MG, Allar M, Taglialatela-Scafati OV, et al,. (2009). Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem 52: 3001-3009.
10. Ashton JS, Wrigth JL, McPartland JM, Tyndall JDA, (2008). Cannabinoid CB1 and CB2 receptor LIGAND specificity and the development of CB2-selective agonists. Curr Med Chem 15: 1428-1443.
11. Bai XM, Jiang H, Ding JX, Peng T, Ma J, Wang YH, et al,. (2010). Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci 86: 214-223.
12. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, Mclauchlan H, et al,. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
13. Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC, Song HS, et al,. (2010). Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact 188: 75-85.
14. Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist CO, et al,. (2008). Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro-Oncol 10: 661-674.
15. 2 and the ligation of PPARγ. J Clin Invest 112: 945-955.
16. Benadiba M, Dos Santos RR, Silvade O, Colquhoun A, (2010). Inhibition of C6 rat glioma proliferation by [Ru2Cl(Ibp)4] depends on changes in p21, p27, Bax/Bcl2 ratio and mitochondrial membrane potential. J Inorg Biochem 104: 928-935.
17. Bhathena SJ, (2006). Relationship between fatty acids and the endocrine and neuroendocrine system. Nutr Neurosci 9: 1-10.
18. Bidwell P, Joh K, Leaver HA, Rizzo MT, (2010). Prostaglandin E2 activates cAMP response element-binding protein in glioma cells via a signaling pathway involving PKA-dependent inhibition of ERK. Prostaglandins Other Lipid Mediat 91: 18-29.
19. Bisogno T, Delton-Vandenbroucke I, Milone A, Lagarde M, Di Marzo V, (1999). Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys 370: 300-307.
20. Bolognini D, Costa D, Maione S, Comelli F, Marini P, Di Marzo V, et al,. (2010). The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677-687.
21. Bröker LE, Kruyt FAE, Giaccone G, (2005). Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
22. Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, et al,. (2010). Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31: 1584-1591.
23. Brown I, Wahle KW, Cascio MG, Smoum-Jaouni R, Mechoulam R, Pertwee RG, et al,. (2011). Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 85: 305-310.
24. Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, et al,. (2009). Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation 6: 5.
25. Carrasco E, Casper D, Werner P, (2007). PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J Neurosci Res 85: 3109-3117.
26. Carrasco E, Werner P, Casper D, (2008). Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci Lett 441: 44-49.
27. Cha B, Kim KH, Kim H, (2009). 15-Deoxy-delta 12, 14,-prostaglandin J2 suppresses nuclear factor-kappaB-mediated apoptosis of Helicobacter pylori-infected gastric epithelial cells. Ann N Y Acad Sci 1171: 457-463.
28. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM, (2001). PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7: 48-52.
29. 2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 1766: 104-119.
30. Chen KC, Chang LS, (2009). Arachidonic acid-induced apoptosis of human neuroblastoma SK-N-SH cells is mediated through mitochondrial alteration elicited by ROS and Ca2+-evoked activation of p38α MAPK and JNK1. Toxicology 262: 199-206.
31. Chima RS, Hake PW, Piraino G, Mangeshkar P, O'Connor M, Zingarelli B, (2010). Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock. Int J Clin Exp Med 3: 1-9.
32. Chu SH, Lim JW, Kim KH, Kim H, (2003). NF-kappaB and Bcl-2 in Helicobacter pylori-induced apoptosis in gastric epithelial cells. Ann N Y Acad Sci 1010: 568-572.
33. Clarke SD, Turini M, Jump D, (1997). Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms. Prostaglandins Leukot Essent Fatty Acids 57: 65-69.
34. Colquhoun A, (2010). Lipids, mitochondria and cell death: implications in neuro-oncology. Mol Neurobiol 42: 76-88.
35. Combrinck M, Williams J, De Berardinis MA, Warden D, Puopolo M, Smith AD, et al,. (2006). Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 77: 85-88.
36. Craib SJ, Ellington HC, Pertwee RG, Ross RA, (2001). A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea pig bronchus. Br J Pharmacol 134: 30-37.
37. Cui PH, Petrovic N, Murray M, (2011). The W-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAPK activation and cyclin D1/CRK4 down-regulation. Br J Pharmacol 162: 1143-1155.
38. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al,. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507.
39. Davidson J, Abul HT, Milton AS, Rotondo D, (2001). Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. Pflugers Arch 442: 526-533.
40. Deigner HP, Hermetter A, (2008). Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr Opin Lipidol 19: 289-294.
41. 2 mRNA in human meningiomas. Mediators Inflamm 2009: 689430.
42. Echeverria V, Clerman A, Dore S, (2005). Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci 22: 2199-2206.
43. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G, (2009). Aspirin, salicylates, and cancer. Lancet 373: 1301-1309.
44. Esquenazi S, Bazan H, (2010). Role of platelet-activating factor in cell death signaling in the cornea. Mol Neurobiol 42: 32-38.
45. 2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 12: 245-260.
46. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al,. (2007). Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14: 1237-1243.
47. Galluzzi L, Morselli E, Vicencio JM, Kepp O, Joza N, Tajeddine N, et al,. (2008). Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans 36: 786-790.
48. Geng Y, Kohli L, Klocke BJ, Roth KA, (2010). Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro-Oncol 12: 473-481.
49. 2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 83: 112-120.
50. Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, et al,. (2009). Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARγ. Biochimie 91: 457-465.
51. Govoni S, Masoero E, Favalli L, Rozza A, Scelsi R, Viappiani S, et al,. (2001). The cyclooxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci Lett 303: 91-94.
52. 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
53. Hardingham GE, Patani R, Baxter P, Wyllie DJ, Chandran S, (2010). Human embryonic stem cell-derived neurones as a tool for studying neuroprotection and neurodegeneration. Mol Neurobiol 42: 97-102.
54. Hardwick JP, Chiang JY, (2009). PPARs, RXRs, and drug-metabolizing enzymes. PPAR Res 2009: 589626.
55. Harr MW, Distelhorst CW, (2010). Apoptosis and autophagy: decoding calcium signals that mediate life or death. Cold Spring Harb Perspect Biol 2: a005579.
56. Hertting G, Seregi A, (1989). Formation and function of eicosanoids in the central nervous system. Ann N Y Acad Sci 559: 84-99.
57. Hoffman T, Lizzio EF, Suissa J, Rotrosen D, Sullivan JA, Mandell GL, et al,. (1988). Dual stimulation of phospholipase activity in human monocytes. Role of calcium-dependent and calcium-independent pathways in arachidonic acid release and eicosanoid formation. J Immunol 140: 3912-3918.
58. Hoshikawa H, Goto R, Mori T, Mitani T, Mori N, (2009). Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240. Int J Oncol 34: 847-852.
59. Ide T, Egan K, Bell-Parikh LC, FitzGerald GA, (2003). Activation of nuclear receptors by prostaglandins. Thromb Res 110: 311-315.
60. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al,. (2006). Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12: 446-451. (Corrigendum Jan 2010).
61. Jiang B, Liang P, Zhang B, Song J, Huang X, Xiao X, (2009). Role of PPAR-β in hydrogen peroxide-induced apoptosis in human umbilical vein endothelial cells. Atherosclerosis 204: 353-358.
62. Kalyankrishna S, Parmentier JH, Malik KU, (2002). Arachidonic acid-derived oxidation products initiate apoptosis in vascular smooth muscle cells. Prostaglandins Other Lipid Mediat 70: 13-29.
63. Keightley MC, Sales KJ, Jabbour HN, (2010). PGF2alpha-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. BMC Cancer 10: 488.
64. Kilter H, Werner M, Roggia C, Reil JC, Schafers HJ, Kintscher U, et al,. (2009). The PPAR-γ agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes Obes Metab 11: 1060-1067.
65. Kim HJ, Kim MY, Jin H, Kang SS, Lee JH, Chang KC, et al,. (2009). Peroxisome proliferator-activated receptor {delta} regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/Smad3. Circ Res 105: 16-24.
66. Kim S, Lee JJ, Heo DS, (2011). PPARγ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. Biochem Biophys Res Commun 406: 389-395.
67. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, et al,. (2005). AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146.
68. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al,. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11.
69. Kurebayashi Y, Honda Y, (1991). Protection by 16,16-dimethyl prostaglandin E2 and dibutyryl cyclic AMP against complement-mediated hepatic necrosis in rats. Hepatology 14: 545-550.
70. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, et al,. (2008). Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128: 2013-2023.
71. Leaver HA, Hardingham GE, (2010). To die or not to die? Current questions in cell death signaling. Mol Neurobiol 42: 1-3.
72. Leaver HA, Rizzo MT, Whittle IR, (2010). Glioma cell death: cell-cell interactions and signalling networks. Mol Neurobiol 42: 89-96.
73. Lee EO, Shin YJ, Chong YH, (2004). Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. J Neuroimmunol 155: 21-31.
74. Liang X, Wang Q, Hand T, Wu L, Breyer RM, Montine TJ, et al,. (2005a). Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25: 10180-10187.
75. Liang X, Wu L, Hand T, Andreasson K, (2005b). Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem 92: 477-486.
76. Lin TN, Cheung WM, Wu JS, Chen JJ, Lin H, Liou JY, et al,. (2006). 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26: 481-487.
77. Liu JJ, Guo YW, Fang ZG, Si XN, Wu XY, Liu PQ, et al,. (2009a). Activation of peroxisome proliferator-activated receptor-gamma induces apoptosis on acute promyelocytic leukemia cells via downregulation of XIAP. Int J Mol Med 24: 623-632.
78. Liu JJ, Xu Y, Zhang Y, Xiao RZ, Lin DJ, (2009b). Peroxisome proliferator-activated receptor γ (PPAR-γ) agonist rosiglitazone (RGZ) inhibits HL-60 cell growth by induction of apoptosis. Lab Med 40: 297-302.
79. 2. FEBS Lett 580: 4114-4120.
80. Lord-Dufour S, Copland IB, Levros LC, Post M, Das A, Khosla C, et al,. (2009). Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1α: targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells 27: 489-497.
81. Lukiw WJ, Bazan NG, (2010). Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease. A review on the bioactivity of neuroprotectin D1 and apoptosis. Mol Neurobiol 42: 10-16.
82. Mahdi JG, Alkarrawi MA, Mahdi AJ, Bowen ID, Humam D, (2006). Calcium salicylate-mediated apoptosis in human HT-1080 fibrosarcoma cells. Cell Prolif 39: 249-260.
83. Mao JT, Nie WX, Tsu IH, Jin YS, Rao JY, Lu QY, et al,. (2010). White tea extract induces apoptosis in non-small cell lung cancer cells: the role of peroxisome proliferator-activated receptor-{gamma} and 15-lipoxygenases. Cancer Prev Res (Phila) 3: 1132-1140.
84. 2 EP2 receptor in cerebral ischemia. J Neurosci 24: 257-268.
85. Meuillet J, (2011). Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain. Curr Med Chem 18: 2727-2742.
86. Miller TW, Isenberg JS, Roberts DD, (2009). Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev 109: 3099-3124.
87. Mizoguchi Y, Tsutsui H, Miyajima K, Sakagami Y, Seki S, Kobayashi K, et al,. (1987). The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model. Hepatology 7: 1184-1188.
88. Nair RR, Tolentino J, Hazlehurst LA, (2010). The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 80: 602-612.
89. O'Callaghan G, Kelly J, Shanahan F, Houston A, (2008). Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. Br J Cancer 99: 502-512.
90. Orgertman B, Hannun YA, (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616.
91. 2 receptors under conditions of aging and stress and the protective effect of the EP2 agonist butaprost on retinal ischemia. Invest Ophthalmol Vis Sci 50: 3238-3248.
92. Ou Z, Zhao X, Labiche LA, Strong R, Grotta JC, Herrmann O, (2006). Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARγ) and 15d-prostaglandin J2-mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 1096: 196-203.
93. Paterniti I, Esposito E, Mazzon E, Galuppo M, Di Paola R, Bramanti P, et al,. (2010). Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther 333: 465-477.
94. Payne CA, Maleki S, Messina M, O'Sullivan MG, Stone G, Hall NR, et al,. (2008). Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther 7: 3420-3428.
95. Payner T, Leaver HA, Knapp B, Whittle IR, Trifan OC, Miller S, et al,. (2006). Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A. Mol Cancer Ther 5: 1817-1826.
96. Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL, (2009). BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase C beta. Blood 114: 4186-4196.
97. Pereira MP, Hurtado O, Cardenas A, Bosca L, Castillo J, Davalos A, et al,. (2006). Rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 26: 218-229.
98. Pertwee RG, (2006). Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147: S163-S171.
99. Pertwee RG, (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
100. Pertwee RG, (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17: 1360-1381.
101. 2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat 81: 150-161.
102. Picq M, Chen P, Perez M, Lagarde M, (2010). DHA metabolism: targetting the brain and lipoxygenation. Mol Neurobiol 42: 48-51.
103. Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, et al,. (1996). Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 184: 883-891.
104. Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, et al,. (2011). Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 32: 1372-1380.
105. Psaila B, Bussel JB, (2008). Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 143: 16-26.
106. Rader DJ, Daugherty A, (2008). Translating molecular discoveries into new therapies for atherosclerosis. Nature 451: 904-913.
107. Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, et al,. (2009). PPARγ protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 51: 169-174.
108. Rizzo MT, (2011). Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 412: 671-687.
109. Rizzo MT, Leaver HA, (2010). Brain endothelial cell death: modes, signaling pathways, and relevance to neural development, homeostasis, and disease. Mol Neurobiol 42: 52-63.
110. Rizzo MT, Regazzi E, Garau D, Akard L, Dugan M, Boswell HS, et al,. (1999). Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells. Cancer Res 59: 5047-5053.
111. Rizzo MT, Pudlo N, Farrell L, Leaver A, (2002). Specificity of arachidonic acid-induced inhibition of growth and activation of c-jun kinases and p38 mitogen-activated protein kinase in hematopoietic cells. Prostaglandins Leukot Essent Fatty Acids 66: 31-40.
112. Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J, et al,. (2002). Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 301: 900-907.
113. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW, (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41.
114. Rudner J, Elsaesser SJ, Muller AC, Belka C, Jendrossek V, (2010). Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem Pharmacol 79: 10-20.
115. Rush S, Khan G, Bamisaiye A, Bidwell P, Leaver HA, Rizzo MT, (2007). c-jun amino-terminal kinase and mitogen activated protein kinase 1/2 mediate hepatocyte growth factor-induced migration of brain endothelial cells. Exp Cell Res 313: 121-132.
116. Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B, (2009). Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci 29: 2053-2063.
117. Saleem S, Zhuang H, de Brum-Fernandes AJ, Maruyama T, Narumiya S, Dore S, (2007). PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 26: 73-78.
118. Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, et al,. (2002). Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 137: 1163-1172.
119. Serhan CN, Haeggstrom JZ, (2010). Lipid mediators in acute inflammation and resolution: eicosanoids, PAF, resolvins, and PRotectins. In:, Serhan CN, Ward PA, Gilroy PW, (eds). Fundamentals of Inflammation. Cambridge University Press: Cambridge, pp. 153-174.
120. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al,. (2009). Maresins: novel macrophage mediators with potent anti-inflammatory and proresolving actions. J Exp Med 206: 15-23.
121. Shankaranarayanan P, Rossin A, Khanwalkar H, Alvarez S, Alvarez R, Jacobson A, et al,. (2009). Growth factor-antagonized rexinoid apoptosis involves permissive PPARγ/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell 16: 220-231.
122. Sibilia V, Pagani F, Rindi G, Lattuada N, Rapetti D, De Luca V, et al,. (2009). Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk. Br J Pharmacol 154: 688-697.
123. Soares AF, Nosjean O, Cozzone D, D'Orazio D, Becchi M, Guichardant M, et al,. (2005). Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. Biochem Biophys Res Commun 337: 521-525.
124. Sugimoto Y, Narumiya S, (2007). Prostaglandin E receptors. J Biol Chem 282: 11613-11617.
125. 2 and inflammatory responses in the central nervous system. Neuromolecular Med 12: 133-148.
126. Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, et al,. (2009). Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255.
127. Takahashi T, Uehara H, Bando Y, Izumi K, (2008). Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth. Mol Cancer Ther 7: 2807-2816.
128. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A, (2011). Regulation of T-Cell inflammation by SOCS1 and SOCS3 suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways. Arterioscler Thromb Vasc Biol 31: 980-985.
129. Thura M, Hokamura K, Yamamoto S, Maeda M, Furuta K, Suzuki M, et al,. (2009). GIF-0173 protects against cerebral infarction through DP1 receptor activation. Exp Neurol 219: 481-491.
130. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al,. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
131. Uttara B, Singh AV, Zamboni AV, Mahajan RT, (2009). Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7: 65-74.
132. Vartiainen N, Huang CY, Salminen A, Goldsteins G, Chan PH, Koistinaho J, (2001). Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclo-oxygenase inhibition. J Neurochem 76: 480-489.
133. Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, Tasdemir E, et al,. (2008). Senescence, apoptosis or autophagy? When a damaged cell must decide its path-a mini-review. Gerontology 54: 92-99.
134. Vinukonda G, Csiszar A, Hu F, Dummula K, Pandey NK, Zia MT, et al,. (2010). Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. Brain 133: 2264-2280.
135. Wahle KW, Heys SD, Rotondo D, (2004). Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res 43: 553-587.
136. Wan J, Jiang L, Lu Q, Ke L, Li X, Tong N, (2010). Activation of PPARδ up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic beta-cells. Biochem Biophys Res Commun 391: 1567-1572.
137. Wang X, Huang G, Mei S, Qian J, Ji J, Zhang J, (2009). Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma. Biochem Biophys Res Commun 380: 286-291.
138. Warner TD, Mitchell JA, (2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18: 790-804.
139. Weber TJ, Markillie LM, Chrisler WB, Vielhauer GA, Regan JW, (2002). Modulation of JB6 mouse epidermal cell transformation response by the prostaglandin F2alpha receptor. Mol Carcinog 35: 163-172.
140. Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, et al,. (2009a). Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119: 1124-1134.
141. Wu JS, Lin TN, Wu KK, (2009b). Rosiglitazone and PPARγ overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol 220: 58-71.
142. Wyllie AH, (2010). Where O death is thy sting? A brief review of apoptosis biology. Mol Neurobiol 42: 4-9.
143. Xue L, Barrow A, Pettipher R, (2009). Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 182: 7580-7586.
144. Zamuner SR, Bak AW, Devchand PR, Wallace JL, (2005). Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2- derived prostaglandin D2. Am J Pathol 167: 1293-1300.
145. Zhao W, Iskandar S, Kooshki M, Sharpe JG, Payne V, Robbins ME, (2007). Knocking out peroxisome proliferator-activated receptor (PPAR) α inhibits radiation-induced apoptosis in the mouse kidney through activation of NF-kappaB and increased expression of IAPs. Radiat Res 167: 581-591.
146. Zingarelli B, Chima R, O'Connor M, Piraino G, Denenberg A, Hake PW, (2010). Liver apoptosis is age dependent and is reduced by activation of peroxisome proliferator-activated receptor-gamma in hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 298: G133-G141.